ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
40 announcements with these filters
Senores Pharmaceuticals Ltd reported revenue from operations of ₹175.2 Cr (+53.4% YoY) and net profit of ₹36.7 Cr (+103.9% YoY) for Q4 FY26.
Senores Pharmaceuticals reported audited FY26 consolidated total income of ₹679.89 Crore. The board also noted the resignation of the Company Secretary effective June 10, 2026.
Senores Pharmaceuticals scheduled a board meeting on May 14, 2026, to approve audited financial results. The trading window remains closed until 48 hours post-approval.
Senores Pharmaceuticals Limited confirmed it does not meet the SEBI criteria for a 'Large Corporate' as of March 31, 2026. The company reported outstanding borrowings of ₹54.07 Crore for the period ended March 31, 2025. This disclosure is part of routine regulatory compliance regarding debt security issuance frameworks.
Senores Pharmaceuticals Ltd reported net profit of ₹33.6 Cr (+104.9% YoY) for Q3 FY26.
Senores Pharmaceuticals Limited submitted its Reconciliation of Share Capital Audit Report for the quarter ended March 31, 2026. The report confirms a total issued capital of 4,60,53,588 shares, with 100% held in dematerialized form. It also notes a preferential allotment of 11,70,000 convertible equity warrants on March 28, 2026.
Senores Pharmaceuticals Limited submitted its quarterly certificate under Regulation 74(5) for the period ended March 31, 2026. The Registrar and Share Transfer Agent, MUFG Intime India, confirmed the processing of dematerialisation requests within prescribed timelines. This is a routine compliance filing with no material impact on operations.
Senores Pharmaceuticals' US subsidiary has formed a strategic Joint Venture, Amerisyn, LLC, to supply the U.S. Federal Government and defense sectors. This partnership provides a gateway to high-entry-barrier military and veterans affairs contracts, positioning the group for significant international business growth.
Senores Pharmaceuticals Limited's US subsidiary has acquired a 70% stake in Amerisyn, LLC. Following this subscription, Amerisyn, LLC has become a step-down subsidiary of the company. This strategic move expanded the company's pharmaceutical footprint in the United States.
Senores Pharmaceuticals Limited's US subsidiary has formed a new joint venture, Amerisyn, LLC, in North Carolina. The company holds a 70% stake, making Amerisyn a step-down subsidiary. This expansion into the US pharmaceutical market signals a strategic growth move for the group.